Astellas, Thunderbolt deal

Newco Thunderbolt acquired Astellas’ preclinical dual antagonist program targeting BLyS (BAFF) and tumor necrosis factor (TNF) ligand superfamily member 13 ( TNFSF13; APRIL) to treat B cell-mediated disorders, including systemic lupus erythematosus (SLE). The terms are not disclosed. Thunderbolt is the first company launched by Vitesse Biologics LLC (South San Francisco, Calif.). ...